Brief report · 29 Dec 2025
Conference abstractPublished 15 Jul 2013
Identifying role of N-myristoyltransferase in the mTOR signalling cascade of ER-and#945; positive breast cancer cells (MCF-7)
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
B reast cancer is the most common malignancy in women from the western world. Estrogen receptor (ER) is a key regulatory in the malignancy of breast cancer. The status of the ER-α of breast tumours is used for predicting response to endocrine therapy. ER-α can be post-translationally modified multiple ways including but not limited to phosphorylation, acylation and, ubiquitination. ER- α can be phosphorylated on multiple amino acid residues throughout the whole protein and within all major structural domains: the N-terminal A/B domain, the DNA-binding or C domain, the hinge or D domain and, the ligand-binding domain or E domain. When phosphorylation occurs in the N-terminal domain it is associated with good endocrine therapy outcome, while phosphorylation that occurs in the C-terminal domain leads to poor prognosis. For example, phosphorylation of the ER-α at S 118 , S 167 , and S 236 predict better prognosis whereas, T 311 , Y 537 , and S 559 predict poor outcome. This has lead to a phosphorylation score called P7 score that more precisely predicts prognosis. Independent studies suggest ER- α phosphorylated at serine 118 leads to good endocrine therapy prognosis while phosphorylation at tyrosine 537 leads to poor outcome. N- myristoyltransferase (NMT) is an enzyme that modifies proteins by covalently attaching a myristic acid to their N-terminal end. The non-receptor tyrosine kinase pp60cSrc phosphorylates ER- α at tyrosine 537 leading to poor prognosis. Myristoylation of pp60cSrc is essential for its activation. The mTOR pathway member Akt/PKB regulates NMT1 activity thus establishing a crosstalk between mTOR pathway and NMT mediated signalling pathways. Therefore, we investigated mTOR- NMT-cSrc mediated regulation of ER-α in ER-α positive MCF-7 cells by inhibiting mTOR and ER-α. Results suggest increased expression of NMT1 upon down-regulating mTORC1 activity and further activation of NMT mediated signalling pathway such as activation of c-Src. Understanding of ER-α activation mechanism would lead to identification of panel of surrogate markers, which would aid in designing treatment protocols for better endocrine therapy outcomes
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Molecular Biomarkers & Diagnosis.
Commentary · 29 Dec 2025
Molecular Diagnostics: Revolutionizing Precision Healthcare
Commentary · 29 Dec 2025
Genomic Biomarkers Revolutionizing Disease Diagnosis and Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Biomarkers & Diagnosis
- SubjectGenetics & Molecular Biology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Danira Jaksic”
- BylineArticles whose byline prints “Andrew McQuiggin”
- BylineArticles whose byline prints “Leigh Murphy”
- BylineArticles whose byline prints “Anuraag Shrivastav”
